†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

BUSINESS DESCRIPTIONPRODUCT ORIGINATION - DEVELOPMENTAn important decision forum within Nycomed is the Product Council that evaluates,prioritises and decides on the product portfolio. A large part of the portfoliois, and will continue to be in-licensed products. This coincides with Nycomed'sstrategy of being a preferred business partner in the Nordic territory. Anotherimportant part of the portfolio contains products resulting from in-house development.International Product Development (IPD) comprises five functions• International Medical Affairs• International Drug Regulatory Affairs• Intellectual Property Rights• Pharmaceutical Development• Project ManagementThe total IPD staff is approximately 115 people. IPD focus on teamwork basedon strong and competent line functions and cross-functional co-operation. Allmajor development projects are organised in this way.After having been divided on four sites in Austria, Denmark and Norway, IPD wasconsolidated by September 1 st on one site, Roskilde in Denmark. This has enableda more efficient utilisation of the total, combined resource and facilitation of“the learning organisation”.The overall role and responsibility of IPD is to be customer oriented and providesufficient resources and expertise to ensure• professional evaluation of in-licensing and business development opportunitiesas well as in-house generated ideas• quality support as requested to Operations, Marketing & Sales and out-licensing• efficient management of defined international projects /product developmentactivities, including responsibilities for project leadership, clinical developmentfrom phase I and onwards, pharmaceutical development, patent strategiesand regulatory strategies• adequate support to secure regulatory compliance and maintenance ofNycomed’s products/projects–31–